KR890006222A - 활성물질방출용 생체분해가능한 이식시스템 - Google Patents

활성물질방출용 생체분해가능한 이식시스템 Download PDF

Info

Publication number
KR890006222A
KR890006222A KR1019880013156A KR880013156A KR890006222A KR 890006222 A KR890006222 A KR 890006222A KR 1019880013156 A KR1019880013156 A KR 1019880013156A KR 880013156 A KR880013156 A KR 880013156A KR 890006222 A KR890006222 A KR 890006222A
Authority
KR
South Korea
Prior art keywords
active substance
rod
film
carrier material
additives
Prior art date
Application number
KR1019880013156A
Other languages
English (en)
Other versions
KR970006082B1 (ko
Inventor
스트릭커 헤르베르트
엔텐만 귄터
케른 오토
미쉘미카일
지렌베르그 베른트
Original Assignee
디이터 라우디엔, 루돌프 호프만
베링거 인겔하임 케이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디이터 라우디엔, 루돌프 호프만, 베링거 인겔하임 케이지 filed Critical 디이터 라우디엔, 루돌프 호프만
Publication of KR890006222A publication Critical patent/KR890006222A/ko
Application granted granted Critical
Publication of KR970006082B1 publication Critical patent/KR970006082B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Abstract

내용 없음

Description

활성물질방출용 생체분해가능한 이식시스템
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제7도는 폴리락타이드 이식제로부터의 메토트레자트(MTX) 방출곡선을 도시한 것이다.

Claims (16)

  1. 담체물질이 세공-형성제 형태로의 규정량의 첨가제, 약10중량% 이하의 생리학적으로 무해한 용매 또는 가소화제 및/또는 저-분자 폴리락트산을 함유함을 특징으로 하는, 임의의 약제학적 부형제와 함께 폴리-D,L-락타이드를 기본으로 한 담체물질 및 이에 배합된 활성물질로 이루어지는 활성물질 방출용 생체분해가능한 이식시스템.
  2. 제1항에 있어서, 담체물질이 글리콜라이드 함량이 50중량%를 초과하지 않는 클리콜라이드와 D,L-락타이드와의 공중합체로 이루어짐을 특징으로 하는, 활성물질방출용 생체분해가능한 이식시스템.
  3. 제1항 또는 제2항에 있어서, 담체물질이 10중량% 이하의 아세트산 에세테르를 함유함을 특징으로 하는, 활성물질방출용 시스템.
  4. 제1항 내지 제3항중의 어느 한 항에 있어서, 담체물질이 저분자 폴리락트산 및/또는 락토즈를 함유함을 특징으로 하는, 활성물질방출용 시스템.
  5. 제1항 내지 제4항중의 어느 한 항에 있어서, 임의로 적층된 구조로 로드(rod) 형태를 취함을 특징으로 하는, 활성물질방출용 시스템.
  6. 제5항에 있어서, 적어도 한층, 임의로 다-층의 필름을 롤링시켜 로드를 형성함을 특징으로하는, 활성물질방출용 시스템.
  7. 제5항에 있어서, 상이한 조성의 다-층의 롤링된 필름으로 이루어짐을 특징으로하는, 활성물질방출용 시스템.
  8. 제5항에 있어서, 로드가 압출에 의해 제조되고, 임의로 외부층을 가짐을 특징으로하는, 활성물질방출용 시스템.
  9. 제1항 내지 제4항중 어느 한 항에 있어서, 활성물질을 함유한 원통(튜브) 및 활성물질에 대해 불투과성인 외부 케이스로 이루어져 활성물질이 원통내 구멍을 통해 방출됨을 특징으로하는, 활성물질방출용 생체 분해가능한 이식시스템.
  10. 활성물질 및 첨가제를 함유한 중합체 용액을 부어 필름을 형성시키고, 이어서 건조시킨 다음 필름을 적합한 스트립으로 절단시킴을 특징으로 하여, 제1항 내지 제7항중 어느 한 항에 따른 활성물질방출용 시스템을 제조하는 방법.
  11. 활성물질 및 첨가제를 함유한 중합체 용액을 부어서 필름을 형성시키고, 약10%의 잔여 용매 함량으로 건조시킨 후, 필요하다면 추가의 필름 춤을 도포하고 건조시킨 다음, 필름을 롤링시켜 로드를 형성하고 이어서 로드가 목적하는 잔여 용매량에 이를데까지 건조시킴을 특징으로 하여, 제1항 내지 제7항중 어느 한 항에 따른 활성물질방출용 시스템을 제조하는 방법.
  12. 제10항 또는 제11항에 있어서, 상이한 조성의 적어도 두 필름을 롤링시켜 로드를 형성시킴을 특징으로 하는 제7항에 따른 활성물질방출용 시스템을 제조하는 방법.
  13. 중합체, 활성물질 및 첨가제로 이루어진 과립을 임의로 케이싱된 튜브 또는 로드의 형태로 압출시킨후 목적하는 길이로 절단시킴을 특징으로 하여, 제1항 내지 제5항, 제8항 및 제9항중 어느 한 항에 따른 활성물질방출용 시스템을 제조하는 방법.
  14. 수의학을 위한 제1항 내지 제9항중 어느 한 항에 따른 이식제의 용도.
  15. 제1항 내지 제9항중 어느 한 항에 있어서, 활성물질로서 호르몬 또는 세포성장억제제를 함유함을 특징으로 하는 이식제.
  16. 약제학적 조성물을 투여하기 위한 제1항 내지 제9항중 어느 한 항에 따른 이식제의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880013156A 1987-10-09 1988-10-08 활성물질 방출용 생분해성 이식시스템 KR970006082B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3734223.1 1987-10-09
DE19873734223 DE3734223A1 (de) 1987-10-09 1987-10-09 Implantierbares, biologisch abbaubares wirkstofffreigabesystem

Publications (2)

Publication Number Publication Date
KR890006222A true KR890006222A (ko) 1989-06-12
KR970006082B1 KR970006082B1 (ko) 1997-04-23

Family

ID=6338006

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880013156A KR970006082B1 (ko) 1987-10-09 1988-10-08 활성물질 방출용 생분해성 이식시스템

Country Status (17)

Country Link
EP (1) EP0311065B1 (ko)
JP (1) JP2763303B2 (ko)
KR (1) KR970006082B1 (ko)
AT (1) ATE101035T1 (ko)
AU (1) AU609194B2 (ko)
CA (1) CA1333770C (ko)
DE (2) DE3734223A1 (ko)
DK (1) DK175252B1 (ko)
ES (1) ES2061589T3 (ko)
FI (1) FI100302B (ko)
IE (1) IE62505B1 (ko)
IL (1) IL87973A (ko)
NO (1) NO176304C (ko)
NZ (1) NZ226514A (ko)
PH (1) PH30236A (ko)
PT (1) PT88703B (ko)
ZA (1) ZA887535B (ko)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5216050A (en) * 1988-08-08 1993-06-01 Biopak Technology, Ltd. Blends of polyactic acid
US5180765A (en) * 1988-08-08 1993-01-19 Biopak Technology, Ltd. Biodegradable packaging thermoplastics from lactides
US5424346A (en) * 1988-08-08 1995-06-13 Ecopol, Llc Biodegradable replacement of crystal polystyrene
US5444113A (en) * 1988-08-08 1995-08-22 Ecopol, Llc End use applications of biodegradable polymers
US6323307B1 (en) 1988-08-08 2001-11-27 Cargill Dow Polymers, Llc Degradation control of environmentally degradable disposable materials
US5252642A (en) * 1989-03-01 1993-10-12 Biopak Technology, Ltd. Degradable impact modified polyactic acid
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
CA2056384C (en) * 1989-06-05 1998-06-23 Tobin N. Gerhart Bioerodible polymers for drug delivery in bone
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
CH679207A5 (ko) * 1989-07-28 1992-01-15 Debiopharm Sa
DE69101313T2 (de) * 1990-01-30 1994-06-30 Akzo Nv Gegenstand zur gesteuerten wirkstoffabgabe mit einem von einer wand völlig umschlossenen hohlraum und völlig oder teilweise mit einem oder mehreren wirkstoffen gefüllt.
DE69004415D1 (de) * 1990-03-05 1993-12-09 Minnesota Mining & Mfg Vorrichtung zur verzögerten Abgabe von pharmakologisch aktiven Verbindungen ins Ohr.
US5350580A (en) * 1990-03-05 1994-09-27 Minnesota Mining And Manufacturing Company Device and method for extended delivery of pharmacologically active agents to the ear
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5681873A (en) * 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
AU6491898A (en) * 1997-04-04 1998-10-30 Alcan International Limited Aluminum alloy composition and method of manufacture
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
DE19908753C2 (de) * 1999-02-20 2003-10-02 Jenapharm Gmbh Bioabbaubare, injizierbare Oligomer-Polymer-Zusammensetzung
US6306425B1 (en) * 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
US8226598B2 (en) 1999-09-24 2012-07-24 Tolmar Therapeutics, Inc. Coupling syringe system and methods for obtaining a mixed composition
US6702849B1 (en) 1999-12-13 2004-03-09 Advanced Cardiovascular Systems, Inc. Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers
DE60132525T2 (de) 2000-03-22 2009-01-29 Dainippon Ink And Chemicals, Inc. Schlagzäh-modifizierer und diese modifizierer enthaltende polyesterzusammensetzung
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
EP3167872B1 (en) * 2000-07-05 2020-10-14 Allergan, Inc. Methods for treating inflammation-mediated conditions of the eye
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
CA2553381C (en) 2004-01-20 2011-03-22 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8475829B2 (en) * 2006-04-06 2013-07-02 Nupathe Inc. Implants for the treatment of dopamine associated states
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US10588855B2 (en) 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP5982287B2 (ja) 2009-11-09 2016-08-31 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 発毛を刺激する組成物および方法
JP4779169B1 (ja) * 2010-10-27 2011-09-28 Ｎｅｃインフロンティア株式会社 ボタン照明構造、電子機器
RU2641021C2 (ru) 2013-02-15 2018-01-17 Аллерган, Инк. Имплантат для пролонгированной доставки лекарственного средства
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
CA3078555A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL109293C (ko) * 1955-12-22
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
DE3218150C2 (de) * 1982-05-14 1986-09-25 Akzo Gmbh, 5600 Wuppertal Wirkstoff enthaltender Körper für die Langzeitabgabe sowie Verfahren zu dessen Herstellung
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4758435A (en) * 1986-08-11 1988-07-19 American Cyanamid Company Estradiol implant composition and method for preparation
DE3710175A1 (de) * 1987-02-12 1988-08-25 Hoechst Ag Mehrteilige implantierbare arzneizubereitung mit langzeitwirkung

Also Published As

Publication number Publication date
PH30236A (en) 1997-02-05
IL87973A (en) 1992-08-18
EP0311065B1 (de) 1994-02-02
PT88703B (pt) 1992-12-31
DK561588D0 (da) 1988-10-07
EP0311065A1 (de) 1989-04-12
DE3734223A1 (de) 1989-04-20
NO884474D0 (no) 1988-10-07
FI884604A0 (fi) 1988-10-07
DE3887616D1 (de) 1994-03-17
DK561588A (da) 1989-04-10
FI884604A (fi) 1989-04-10
NO884474L (no) 1989-04-10
IE883040L (en) 1989-04-09
NO176304C (no) 1995-03-22
CA1333770C (en) 1995-01-03
NZ226514A (en) 1990-02-26
AU609194B2 (en) 1991-04-26
JP2763303B2 (ja) 1998-06-11
IE62505B1 (en) 1995-02-08
PT88703A (pt) 1988-11-01
ES2061589T3 (es) 1994-12-16
JPH02117A (ja) 1990-01-05
FI100302B (fi) 1997-11-14
ZA887535B (en) 1990-06-27
AU2352288A (en) 1989-04-13
IL87973A0 (en) 1989-03-31
KR970006082B1 (ko) 1997-04-23
NO176304B (no) 1994-12-05
ATE101035T1 (de) 1994-02-15
DK175252B1 (da) 2004-07-19

Similar Documents

Publication Publication Date Title
KR890006222A (ko) 활성물질방출용 생체분해가능한 이식시스템
KR920007643A (ko) 인간 및 수의의 의료에 유용한 물질
EP0514406B1 (en) Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances
FI77372B (fi) Foerfarande foer framstaellning av ett system av ett farmaceutiskt aktivt aemne foer transdermal laongtidsapplikation som en polyakrylatfilm.
US4758434A (en) Article useful for administration of pharmacologically-active substances transdermally, orally, or by means of implant
CN1237103A (zh) 固体的发泡的含活性成分的制剂
DE69121675T2 (de) Mikrosphäre enthaltende pharmazeutische Zusammensetzung mit kontrollierter Freigabe und Verfahren zur Herstellung
KR890004688A (ko) 생활성 물질의 조절성 방출성을 위한 피복 제재
PE20040675A1 (es) Formulaciones de deposito de liberacion controlada
KR100334435B1 (ko) 에멀젼 방법에 의한 다공성 매트릭스형 서방성 제제의 제조방법
RU99107556A (ru) Твердые, вспененные препараты активного начала
EP1638535A1 (en) Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof
EP0040861B1 (en) Polymeric diffusion matrix and method of its preparation
CN102892815A (zh) 熔体挤出的膜
FI118885B (fi) Skopolamiinilaastari
KR970058724A (ko) 지속성 동물 성장 호르몬 제형 및 이의 제조 방법
US5468501A (en) Article useful for administration of pharmacologically-active substances transdermally, orally or by means of implant
CN102905695A (zh) 基于两亲共聚物的具有增大表面积的生物活性物质制剂
Andreopoulos Plasticization of biodegradable polymers for use in controlled release
GR1000266B (el) Μεθοδος παρασκευης μιας συνθεσης βασισμενης σε πολυεστερα για την ελεγχομενη εκλυση φαρμακευτικων ουσιων.
KR880008806A (ko) 경구용 서방성 약제학적 제제
JPS597688B2 (ja) 消炎・鎮痛用貼付剤
Acartürk Investigation of the effect of different adjuvants on felodipine release kinetics from sustained release monolithic films
JPH07132127A (ja) 生理用ナプキン
Naraharisetti et al. In vitro release of gentamicin from implantable discs and modified discs

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110803

Year of fee payment: 15

EXPY Expiration of term